The estimated Net Worth of Karen K. Daniels is at least $442 ezer dollars as of 18 November 2020. Ms. Daniels owns over 5,333 units of Adamis Pharmaceuticals Corp stock worth over $114,916 and over the last 13 years she sold ADMP stock worth over $67,332. In addition, she makes $259,891 as Vice President - Operations at Adamis Pharmaceuticals Corp.
Sign up
Ms. Daniels ADMP stock SEC Form 4 insiders trading
Karen has made over 9 trades of the Adamis Pharmaceuticals Corp stock since 2019, according to the Form 4 filled with the SEC. Most recently she sold 5,333 units of ADMP stock worth $2,187 on 18 November 2020.
The largest trade she's ever made was selling 13,911 units of Adamis Pharmaceuticals Corp stock on 20 March 2019 worth over $31,995. On average, Karen trades about 3,080 units every 32 days since 2011. As of 18 November 2020 she still owns at least 149,242 units of Adamis Pharmaceuticals Corp stock.
You can see the complete history of Ms. Daniels stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Karen Daniels biography
Karen K. Daniels serves as Vice President - Operations of the Company. Ms. Daniels joined Adamis in July 2009 as Vice President of Operations. She has over 30 years of experience in operational and engineering roles across diverse industries including electronics, medical devices, contract manufacturing and pharmaceutical manufacturing. Prior to joining Adamis, Ms. Daniels served as President of Althea Technologies from 2007 to 2009. Althea Technologies is a contract manufacturer for the pharmaceutical industry. She also served as Senior Director of Operations and Logistics for Vidacare, a medical device manufacturer from 2006 to 2007. From 2003 to 2006, she was President of Lambda Power. Ms. Daniels received a B.S. degree from the University of Arizona.
What is the salary of Karen Daniels?
As the Vice President - Operations of Adamis Pharmaceuticals Corp, the total compensation of Karen Daniels at Adamis Pharmaceuticals Corp is $259,891. There are 5 executives at Adamis Pharmaceuticals Corp getting paid more, with Dennis Carlo having the highest compensation of $1,770,310.
How old is Karen Daniels?
Karen Daniels is 67, she's been the Vice President - Operations of Adamis Pharmaceuticals Corp since 2009. There are 7 older and 6 younger executives at Adamis Pharmaceuticals Corp. The oldest executive at Adamis Pharmaceuticals Corp is Dr. Dennis J. Carlo, 78, who is the Pres, CEO & Director.
What's Karen Daniels's mailing address?
Karen's mailing address filed with the SEC is C/O ADAMIS PHARMACEUTICALS CORPORATION, 11682 EL CAMINO REAL, STE 300, SAN DIEGO, CA, 92130.
Insiders trading at Adamis Pharmaceuticals Corp
Over the last 14 years, insiders at Adamis Pharmaceuticals Corp have traded over $2,051,720 worth of Adamis Pharmaceuticals Corp stock and bought 87,550 units worth $188,843 . The most active insiders traders include Ahmed Shayan Fazlur Eses Ho..., Dennis J Phd Carlo és David J. Marguglio. On average, Adamis Pharmaceuticals Corp executives and independent directors trade stock every 34 days with the average trade being worth of $12,919. The most recent stock trade was executed by Dennis J Phd Carlo on 25 May 2022, trading 250,000 units of ADMP stock currently worth $192,500.
What does Adamis Pharmaceuticals Corp do?
adamis pharmaceuticals corporation (nasdaq: admp) is a specialty biopharmaceuticals company focused on developing and commercializing products in the therapeutic areas of respiratory disease, allergies, oncology and immunology. its specialty pharmaceutical division currently has four products in its pipeline including the epinephrine injection pre-filled syringe (pfs) for use in the emergency treatment of anaphylaxis, apc-1000 and apc-5000 (dry powder inhaler) for the treatment of asthma and chronic obstructive pulmonary disease (copd), and apc-3000, a hydrofluoroalkane (hfa) inhaled nasal steroid product for the treatment of allergic rhinitis. this division’s focus is to create low cost therapeutic alternatives to existing treatments in large markets. adamis will pursue 505(b)(2) regulatory approval filings in order to minimize costs and shorten the time to market in this division. within its biotechnology division, the company has four products under development include telob-vax, a
What does Adamis Pharmaceuticals Corp's logo look like?
Complete history of Ms. Daniels stock trades at Adamis Pharmaceuticals Corp
Adamis Pharmaceuticals Corp executives and stock owners
Adamis Pharmaceuticals Corp executives and other stock owners filed with the SEC include:
-
Dennis Carlo,
President, Chief Executive Officer, Director -
Ronald Moss,
Chief Medical Officer -
Robert Hopkins,
Chief Financial Officer, Senior Vice President - Finance -
Dr. Dennis J. Carlo,
Pres, CEO & Director -
David Marguglio,
Senior Vice President, Chief Business Officer and Director -
Karen Daniels,
Vice President - Operations -
Richard Williams,
Independent Chairman of the Board, Consultant -
David J. Marguglio,
Sr. VP, Chief Bus. Officer & Director -
Mark Flather,
Director, Investor Relations and Corporate Communications -
Roshawn Blunt,
Independent Director, Consultant -
Howard Birndorf,
Independent Director, Consultant -
Robert B. Rothermel,
Consultant -
Eddie Wabern Glover,
Chief Exec. Officer of US Compounding Inc -
Jennifer C. Suski,
Sr. Director of Marketing -
Karen K. Daniels,
VP of Operations -
David C. Benedicto,
Chief Financial Officer -
Thomas Moll,
Vice President of Research -
William C Denby,
Director -
Eddie Wabern Glover,
CEO of US Compounding, Inc. -
Robert B Rothermel,
Director -
Ahmed Shayan Fazlur Eses Ho...,
-
Tina Susan Nova,
Director -
Kenneth M Cohen,
Director -
Craig A Johnson,
Director -
Meera J. Desai,
Director -
David C. Benedicto,
Chief Financial Officer -
Vickie S Reed,
Director -
Ebrahim Versi,
CEO -
Jannine Versi,
Director